India’s pharmaceutical sector opened FY27 with mixed but largely positive results across exports, domestic sales, and global markets. Pharma exports rose 6.8 percent year over year to USD 8.1 billion in Q1 FY27. Several drugmakers also...
Gland Pharma reported a strong Q1 profit. The company posted revenue of INR 1,800.27 crore in Q1 FY27. Its net profit rose 47.1% year over year to INR 316.95 crore.
India’s MedTech industry is entering a new phase of growth as domestic manufacturing, technology innovation, global partnerships, and healthcare demand reshape the medical devices sector.
Samsung Bioepis has launched its aflibercept biosimilar OPUVIZ in both vial and pre-filled syringe formats, marking an entry to Europe’s eye drug market
Akums Drugs and Pharmaceuticals has started FY27 on a strong note, with Q1 profit surging 55 percent year-on-year.
Medical device manufacturing in India is set to enter a new shift as the government strengthens its push to build an export-oriented ecosystem
Biocon delivered a strong start to FY27 with a sharp rise in earnings. The company's Q1 profit jumped four times year-on-year, supported by steady biosimilars demand. Revenue also increased, reflecting healthy growth across its key business segments.
Quarterly Earnings took the spotlight after Pfizer reported better-than-expected second-quarter results. However, the company made it clear that its focus extends beyond one strong quarter.
Retatrutide Early Access has started for a limited group of patients before its expected FDA approval. Eli Lilly has launched an expanded access program for eligible adults with severe obesity.
Moderna has beaten Wall Street revenue estimates just days before a major US regulatory decision. The quarterly revenue surprise comes as the company prepares for the FDA's verdict on its flu vaccine.
, CDSCO.jpg)